Earnings call transcript: Evolv Technologies Q4 2025 reports revenue growth

Evolv reported Q4 2025 revenue of $38.5M (+32% YoY), beating consensus $36.43M by 5.68%, while EPS was a loss of $0.03 (missed by $0.01). Adjusted EBITDA was $1.8M (4.7% margin), adjusted gross margin fell to 50% from 62% due to a shift to direct fulfillment, and cash rose $12.8M sequentially to $69M; ARR ended 2025 at $120.5M. Management raised FY2026 revenue guidance to roughly $172–$178M (midpoint ~$174.26M) and expects ARR of $145–150M, driving a 10.58% after-hours stock jump to $5.75; key risks remain margin pressure from the new fulfillment model, competition, supply-chain and regulatory changes.

Analysis

The company’s pivot to capture more of the hardware revenue in‑house is a classic economic trade: near-term margin percent compression for permanently higher gross profit dollars and greater revenue visibility. The most important second‑order effect is the RPO/ARR composition shift — more backlog converted to on‑balance-sheet revenue increases reported top‑line but defers some margin recovery until manufacturing and service scale, so expectations for rapid margin re‑expansion should be timed to operational milestones, not the headline beat cycle.

Contract manufacturing (and supply chain) is the nonlinear lever here. A successful ramp with an external CM partner will both reduce per‑unit COGS and shrink working capital needs; a delay or quality snag would re‑expose margins and cash conversion to volatility. Similarly, attach‑rate dynamics for the new bag‑screening product are the high‑leverage growth driver: multi‑product installs expand lifetime value and shorten payback, but failure to sustain attach rates would leave ARR growth exposed to new‑logo variability.

Regulatory pushes and public‑sector procurement create a multi‑year demand runway but concentrate exposure to public budgets and politics — adoption is lumpy and often follows legislative cycles. Nearer term (quarters) catalysts to watch are: trancheable unit deployments, CM ramp milestones, and actual cash conversion vs. adjusted EBITDA; any miss on those operational read‑throughs will compress the re‑rating that investors have already baked into the stock.

Key Decisions for Investors

• Buy a risk‑defined long on EVLVW (6–9 month call spread). Rationale: asymmetric upside if attach rates and CM ramp deliver incremental ARR cadence; capped premium limits downside from multiple near‑term macro/seasonal risks. Size 0.5–1.0% of fund notional; target 2x–3x return if operational milestones hit; stop if premium loses 50%.
• Establish a medium‑term (6–12 month) long in PLXS (outright equity or LEAP calls) to play contract manufacturing tailwind. Rationale: margin and working‑capital relief accrues to the OEM via a successful ramp. Position 0.5% AUM; downside is schedule slippage or lower volumes — mark to event (ramp verification) and take partial profits on confirmation.
• Buy SMCI (6–18 month) to capture incremental on‑prem inference/AI hardware demand from hardware‑enabled SaaS vendors consolidating model inference away from cloud. Rationale: durable secular AI spend offsets some cyclic risk in hardware markets. Keep allocation small (0.5% AUM); expect 30–60% upside probability if visibility into enterprise inference projects improves.
• Near‑term hedge: purchase short‑dated out‑of‑the‑money EVLVW puts or sell into any melt‑up post‑release. Rationale: protects against a quick reversion if margins/mix commentary disappoints or if public procurement news stalls. Hedge size should offset 25–50% of net long exposure; cost treated as insurance ahead of operational readouts.